917363-80-5Relevant articles and documents
Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity
Li, Yiwei,Liang, Jun,Siu, Tony,Hu, Essa,Rossi, Michael A.,Barnett, Stanley F.,Defeo-Jones, Deborah,Jones, Raymond E.,Robinson, Ronald G.,Leander, Karen,Huber, Hans E.,Mittal, Sachin,Cosford, Nicholas,Prasit, Peppi
scheme or table, p. 834 - 836 (2009/09/25)
A series of [1,2,4]triazolo[3,4-f][1,6]naphthyridine allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been shown to have potent dual Akt1 and 2 cell potency. The representative compound 13 provided potent inhibitory activity against Akt1 and 2 in vivo in a mouse model.
INHIBITORS OF AKT ACTIVITY
-
Page/Page column 92, (2010/11/25)
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.